The following is a summary of "Variations in Antithrombotic Prescriptions and Evaluation of Extended Clopidogrel Therapy ...

and to reduce the risk of major thrombotic vascular events in adults with peripheral artery disease (PAD), including patients ...

including patients after recent lower extremity revascularization due to symptomatic PAD. Rivaroxaban tablets 2.5 mg (RLD Xarelto) had a market value of roughly $446 million, per IQVIA January ...

CLICK TO TWEET: Late-breaking data at #ACC21 offer insights on long-term prevention of future thrombotic events in patients with #PAD after lower-extremity revascularization. Full @JanssenUS press ...